Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)--Mar. 30, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex , a leader in preclinical digital pathology software-as-a-service.
View HTML
Toggle Summary Charles River Laboratories To Participate In Barclays Global Healthcare Conference
WILMINGTON, Mass. --(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference . The Company will present on Wednesday, March 11 th , at 10:15 a.m. ET .
View HTML
Toggle Summary Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
WILMINGTON, Mass. --(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews , M.D., Ph.D., to its Board of Directors, effective February 28, 2020 . Dr. Andrews is Duke University’s Dean Emerita of its School of Medicine, Vice
View HTML
Toggle Summary Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
– Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 – – Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 – – Provides 2020 Guidance –
View HTML
Upcoming Events
There are currently no events scheduled.

Featured Report

2019 Annual Report (PDF)